[email protected] (Reuben Gregg Brewer)

Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Johnson & Johnson doesn't need GLP-1 drugs to grow, and that's good news for long-term investors.